SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001731122-24-000758
Filing Date
2024-05-09
Accepted
2024-05-09 08:00:30
Documents
14
Period of Report
2024-05-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K e5655_8-k.htm   iXBRL 8-K 24103
2 EXHIBIT 99.1 e5655_ex99-1.htm EX-99.1 78281
  Complete submission text file 0001731122-24-000758.txt   286392

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE avxl-20240509.xsd EX-101.SCH 3009
4 XBRL LABEL FILE avxl-20240509_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE avxl-20240509_pre.xml EX-101.PRE 22355
17 EXTRACTED XBRL INSTANCE DOCUMENT e5655_8-k_htm.xml XML 3683
Mailing Address 630 5TH AVENUE 20TH FLOOR NEW YORK NY 10111
Business Address 630 5TH AVENUE 20TH FLOOR NEW YORK NY 10111 844-689-3939
ANAVEX LIFE SCIENCES CORP. (Filer) CIK: 0001314052 (see all company filings)

IRS No.: 980608404 | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37606 | Film No.: 24928672
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)